Clinical Trials Sponsored by BioGene Pharmaceutical

Total 20512 results

Biogen

Terminated

Tecfidera Slow-Titration Study (TITRATION)

Multiple Sclerosis

United States, Belgium, Czech Republic, Italy
Biogen

Completed

Efficacy and Safety Study of Prolonged-Release Fampridine in Participants With Multiple Sclerosis (ENHANCE)

Multiple Sclerosis

United States, Finland, Italy, United Kingdom, Bulgaria, Serbia, Russian Federation, Lithuania, Poland, Czech Republic, Netherlands
Biogen

Completed

Observational Study to Characterize Real-world Clinical Outcomes With Relapsing-remitting Multiple Sclerosis (RRMS) (EFFECT)

Multiple Sclerosis

United States, Italy, Hungary, United Kingdom, Spain, France, Australia, Germany, Canada, Switzerland, Argentina, Czech Republic, Croatia
Biogen

Completed

Phase 4 Gastrointestinal Tolerability Study of Dimethyl Fumarate in Patients With Relapsing Forms of Multiple Sclerosis in the United States (MANAGE)

Relapsing Forms of Multiple Sclerosis

United States
Biogen

Completed

Open-Label Study to Assess the Effect of Long-Term Prolonged-Release Fampridine (BIIB041) on Quality of Life as Reported by Participants With Multiple Sclerosis (ENABLE)

Multiple Sclerosis

France, Italy, United Kingdom, Germany, Australia, Belgium, Netherlands, Portugal, Denmark
Biogen

Completed

Characterize Flu-like Symptoms in Relapsing Multiple Sclerosis Patients Transitioning From Non-Pegylated Interferon Beta (IFN-β) Therapies to Peginterferon Beta-1a (BIIB017) (ALLOW)

Relapsing Multiple Sclerosis

United States
Biogen

Terminated

BIIB023 Proof-of-Concept Study in Participants With Lupus Nephritis (ATLAS)

Lupus Nephritis

United States, Peru, Belgium, Italy, Philippines, Malaysia, Hong Kong, Argentina, Germany, Hungary, Australia, Colombia, Russian Federation, Portugal, Mexico, Korea, Republic of, France, Thailand, Brazil, Poland, Spain
Biogen

Terminated

BIIB023 Long-Term Extension Study in Subjects With Lupus Nephritis

Lupus Nephritis

Belgium, Peru, Italy, Malaysia, Australia, Argentina, United States, Hong Kong, Hungary, Poland, Colombia, Russian Federation, Philippines, Brazil, France, Korea, Republic of, Mexico, Spain, Thailand
Biogen

Completed

Absolute Bioavailability of a Single, Fixed Subcutaneous Dose of Aducanumab in Healthy Participants

Alzheimer's Disease

United States
Biogen

Terminated

Fampridine Pregnancy Exposure Registry

Multiple Sclerosis | Pregnancy

France
Biogen

Completed

Tecfidera Lymphocyte Chart Review (REALIZE)

Multiple Sclerosis

United States
Biogen

Completed

Study to Assess the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers

Healthy

United States
Biogen

Completed

Real-world Outcomes on Tecfidera (BG00012, Dimethyl Fumarate) Post-Tysabri (BG00002, Natalizumab) (STRATEGY)

Relapsing-Remitting Multiple Sclerosis

United States
Biogen

Withdrawn

Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)

Relapsing-Remitting Multiple Sclerosis | Relapsing Forms of Multiple Sclerosis
Biogen

Terminated

BG9924 in Combination With Methotrexate Extension of Study 104RA203 (NCT 00458861)

Rheumatoid Arthritis

United States, Belgium, Canada, United Kingdom
Biogen

Completed

Assessment Of The Safety And Efficacy Of BG9924 In Rheumatoid Arthritis (RA) Participants (RESPOND)

Rheumatoid Arthritis

Argentina, Mexico, Romania, Brazil, Hungary, Poland, Russian Federation, United Kingdom
Biogen

Terminated

Canadian Multicenter Observational Study of Tysabri in Early Relapsing Remitting Multiple Sclerosis Participants (COSTAN)

Relapsing-Remitting Multiple Sclerosis

Canada
Biogen

Completed

Hormone Receptor Positive Metastatic Breast Cancer (HR+ mBC) BIIB021 Plus Aromasin Schedule Finding

Breast Cancer

United States, Russian Federation, Australia, Belgium
Biogen

Terminated

Lumiliximab With Fludarabine, Cyclophosphamide, and Rituximab (FCR) Versus FCR Alone in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL) (LUCID)

Chronic Lymphocytic Leukemia

United States, Brazil, Czech Republic, Italy, Russian Federation, Spain, United Kingdom, Lithuania, Poland, Romania, Australia, Argentina, Austria, Canada, France, Israel, New Zealand, Portugal, Slovakia, Greece, Germany, India, Bel...
Biogen

Completed

TYSABRI Global Observational Program in Safety (TYGRIS)

Multiple Sclerosis

United States
Biogen

Completed

Functional MRI in Lupus Nephritis

Healthy | Lupus Nephritis

United States
Biogen

Completed

Single Ascending Dose Study of BIIB037 in Participants With Alzheimer's Disease

Alzheimer's Disease

United States
Biogen

Completed

BG00012 Regional Absorption Study

Healthy

United Kingdom
Biogen

Completed

Phase 1 Subcutaneous Single and Multiple Ascending Dose Study of BG00010 (Neublastin)

Healthy | Painful Lumbar Radiculopathy

Netherlands
Biogen

Completed

Single Ascending Dose Study of the Safety, Tolerability, and Pharmacokinetics of BIIB061 in Healthy Adult Volunteers Including Absolute Bioavailability and Food Effect

Healthy

United States
Biogen

Completed

Efficacy and Safety Study of Oral BG00012 With Active Reference in Relapsing-Remitting Multiple Sclerosis (CONFIRM)

Relapsing-Remitting Multiple Sclerosis

United States, Croatia, Bulgaria, Czech Republic, France, Mexico, Poland, Spain, Germany, Belarus, Estonia, Latvia, Romania, Ukraine, Israel, New Zealand, Slovakia, Greece, India, Serbia, Ireland, Costa Rica, Canada, Belgium, Macedonia,... and more
Biogen

Terminated

Genetic Evaluation of Natalizumab-Treated Patients With Progressive Multifocal Leukoencephalopathy

Progressive Multifocal Leukoencephalopathy

United States, Germany
Biogen

Completed

Study of the Safety, Tolerability, Pharmacokinetics and Safety of BG00010 (Neublastin) in Subjects With Sciatica.

Sciatica

Netherlands
Biogen

Completed

A Proof of Concept Study to Evaluate the Effectiveness of Tysabri in Relapsing Remitting Multiple Sclerosis (RRMS) Patient Bladder Function (TRUST)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

JC-virus (JCV) Epidemiology in Multiple Sclerosis (MS) (JEMS)

Multiple Sclerosis
Biogen

Completed

A Single-Dose, Pharmacokinetic/Pharmacodynamic (PK/PD), & Safety Study of BIIB017 in Participants With Renal Impairment & Healthy Volunteers

Healthy | Renal Insufficiency
Biogen

Completed

PeptoBismol® Use to Reduce Gastrointestinal Events in Healthy Volunteers Receiving DMF [Tecfidera®] Twice Daily

Healthy

United States
Biogen

Completed

Is IFN-beta Treatment in MS Useful After a Washout Period in Patients With Neutralizing Antibodies to Interferon Beta (RENeu)

Relapsing-Remitting Multiple Sclerosis

New Zealand, Australia
Biogen

Completed

Avonex Safety and Tolerability in Chinese Subjects With Relapsing Multiple Sclerosis (MS) (Avonex China)

Multiple Sclerosis

China
Biogen

Completed

Avonex (Interferon-beta-1a) and Avonex Plus Methylprednisolone for the Treatment of Relapsing-remitting MS

Relapsing-remitting Multiple Sclerosis

Belgium, Denmark, Finland, Netherlands, Norway, Sweden, Switzerland, United Kingdom
Biogen

Completed

MATRIX: Measuring Neutralizing Antibodies in the Patients Treated With Interferon Beta 1a IM, in Mexico and Colombia (MATRIX)

Multiple Sclerosis

Colombia, Mexico
Biogen

Completed

Effect of Food and Antacid on BIIB021 With Advanced Solid Tumors

Advanced Solid Tumors

United States
Biogen

Completed

Study in Healthy Volunteers to Establish the Bioequivalence of Two Different Manufacturers.

Healthy Volunteers

United States
Biogen

Terminated

Safety and Activity of 90Y-Labeled IDEC-159 in Subjects With Metastatic Colorectal Adenocarcinoma

Colorectal Cancer | Metastases

United States
Biogen

Completed

Study to Determine if Avonex and Rebif Work Comparably Well in Subjects With Relapsing Multiple Sclerosis (PROOF)

Multiple Sclerosis

United States, Australia, Austria, Canada
Biogen

Withdrawn

A Proof-of-Concept Study to Correlate Retinal Nerve Fiber Layer Changes in Patients With Multiple Sclerosis Treated With Natalizumab or Interferon Beta 1-a (PRTOECT)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Dose-Finding Safety Study of BIIB014 in Combination With Levodopa in Moderate to Late Stage Parkinson's Disease

Parkinson's Disease

United Kingdom, Israel, India
Biogen

Completed

GER-009-06-AVX Early Therapy in Multiple Sclerosis (FIT)

Relapsing-Remitting Multiple Sclerosis
Biogen

Completed

Patient Satisfaction Study of Single-Use Autoinjector for the Delivery of Pre-Filled Avonex Syringe

Multiple Sclerosis
Biogen

Completed

A Bioequivalence Study of Serum Free Avonex and Serum Containing Avonex in Healthy Volunteers

Multiple Sclerosis
Biogen

Completed

Does Quality of Life Improve in Multiple Sclerosis Patients Treated With Interferon Beta-1a? (FLAIR)

Relapsing Remitting Multiple Sclerosis

Belgium, Luxembourg, United Kingdom
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Biogen

Completed

Treatment of Relapsed Low-Grade or Follicular Lymphoma With Rituximab (Also Known as Rituxan, IDEC-C2B8, IDEC-102)

Low-Grade or Follicular B-Cell Non-Hodgkin's Lymphoma

United States, Canada
Biogen

Recruiting

A Study to Evaluate the Pharmacokinetics, Safety and Immunogenicity of BIIB800 Subcutaneously (SC) Compared to Actemra® in Healthy Male Participants

Healthy Volunteer

United States
Biogen

Recruiting

A Study to Evaluate Safety and Efficacy of BIIB091 in Participants With Relapsing Forms of Multiple Sclerosis (FUSION)

Relapsing Forms of Multiple Sclerosis

Spain, United States, Italy, Switzerland, Germany, Bulgaria, Czechia, Poland, Puerto Rico, Romania

3

Subscribe